Central conducting lymphatic anomaly (CCLA) is a heterogenous disorder caused by disruption of central lymphatic flow that may result in dilation or leakage of central lymphatic channels. There is also a paucity of known genetic diagnoses associated with CCLA. We hypothesized that specific genetic syndromes would have distinct lymphatic patterns and this would allow us to more precisely define CCLA. As a first step toward “precision lymphology”, we defined the genetic conditions associated with CCLA by performing a retrospective cohort study. Individuals receiving care through the Jill and Mark Fishman Center for Lymphatic Disorders at the Children’s Hospital of Philadelphia between 2016 and 2019 were included if they had a lymphangiogram and clinical genetic testing performed and consented to a clinical registry. In our cohort of 115 participants, 26% received a molecular diagnosis from standard genetic evaluation. The most common genetic etiologies were germline and mosaic RASopathies, chromosomal abnormalities including Trisomy 21 and 22q11.2 deletion syndrome, and PIEZO1-related lymphatic dysplasia. Next, we analyzed the dynamic contrast magnetic resonance lymphangiograms and found that individuals with germline and mosaic RASopathies, mosaic KRASopathies, PIEZO1-related lymphatic dysplasia, and Trisomy 21 had distinct central lymphatic flow phenotypes. Our research expands the genetic conditions associated with CCLA and genotype-lymphatic phenotype correlations. Future descriptions of CCLA should include both genotype (if known) and phenotype to provide more information about disease (gene-CCLA). This should be considered for updated classifications of CCLA by the International Society of Vascular Anomalies.
Your institute does not have access to this article
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
The data that support this study are available in the tables and Supplementary Tables. Additional data is not available due to privacy restrictions.
Makinen T, Boon LM, Vikkula M, Alitalo K. Lymphatic malformations: genetics, mechanisms and therapeutic strategies. Circ Res. 2021;129:136–54.
Ricci KW, Iacobas I. How we approach the diagnosis and management of complex lymphatic anomalies. Pediatr Blood Cancer. 2021;e28985. https://doi.org/10.1002/pbc.28985.
Clemens RK, Pfammatter T, Meier TO, Alomari AI, Amann-Vesti BR. Combined and complex vascular malformations. Vasa. 2015;44:92–105.
Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics. 2015;136:e203–14.
Dori Y, Zviman MM, Itkin M. Dynamic contrast-enhanced MR lymphangiography: feasibility study in swine. Radiology. 2014;273:410–6.
Dori Y. Novel lymphatic imaging techniques. Tech Vasc Interventional Radiol. 2016;19:255–61.
Biko DM, Reisen B, Otero HJ, Ravishankar C, Victoria T, Glatz AC, et al. Imaging of central lymphatic abnormalities in Noonan syndrome. Pediatric Radiol. 2019;49:586–92.
Mills M, van Zanten M, Borri M, Mortimer PS, Gordon K, Ostergaard P, et al. Systematic review of magnetic resonance lymphangiography from a technical perspective. J Magn Reson Imaging. 2021;53:1766–90.
Li D, Wenger TL, Seiler C, March ME, Gutierrez-Uzquiza A, Kao C, et al. Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly. Hum Mol Genet. 2018;27:3233–45.
Li D, March ME, Gutierrez-Uzquiza A, Kao C, Seiler C, Pinto E, et al. ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. Nat Med. 2019;25:1116–22.
Li D, Sheppard SE, Peroutka C, Barnes C, Reid JR, Smith CL, et al. Expanded phenotypic spectrum of JAG1-associated diseases: Central conducting lymphatic anomaly with a pathogenic variant in JAG1. Clin Genet. 2021;99:742–3.
Dori Y, Smith C, Pinto E, Snyder K, March ME, Hakonarson H, et al. Severe lymphatic disorder resolved with MEK inhibition in a patient with Noonan syndrome and SOS1 mutation. Pediatrics 2020;146:e20200167.
Byrne AB, Brouillard P, Sutton DL, Kazenwadel J, Montazaribarforoushi S, Secker GA, et al. Pathogenic variants in MDFIC cause recessive central conducting lymphatic anomaly with lymphedema. Sci Transl Med. 2022;14:eabm4869.
Joyce S, Gordon K, Brice G, Ostergaard P, Nagaraja R, Short J, et al. The lymphatic phenotype in Noonan and Cardiofaciocutaneous syndrome. Eur J Hum Genet. 2016;24:690–6.
Lissewski C, Chune V, Pantaleoni F, De Luca A, Capri Y, Brinkmann J, et al. Variants of SOS2 are a rare cause of Noonan syndrome with particular predisposition for lymphatic complications. Eur J Hum Genet. 2021;29:51–60.
Traub ES, Sheppard SE, Dori Y, Burns KD, Zackai EH, Ware SM, et al. Chromosome 4q28.3q32.3 duplication in a patient with lymphatic malformations, craniosynostosis, and dysmorphic features. Clin Dysmorphol. 2021;30:89–92.
Fotiou E, Martin-Almedina S, Simpson MA, Lin S, Gordon K, Brice G, et al. Novel mutations in PIEZO1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis. Nat Commun. 2015;6:8085.
Biko DM, Smith CL, Otero HJ, Saul D, White AM, DeWitt A, et al. Intrahepatic dynamic contrast MR lymphangiography: initial experience with a new technique for the assessment of liver lymphatics. Eur Radio. 2019;29:5190–6.
Biesecker LG, Adam MP, Alkuraya FS, Amemiya AR, Bamshad MJ, Beck AE, et al. A dyadic approach to the delineation of diagnostic entities in clinical genomics. Am J Hum Genet. 2021;108:8–15.
The authors thank the patients, their families, and the other clinicians that have helped care for the individuals in this study. We thank Lymphatic Center, CAG and CVAP team members for their insightful comments and discussion.
Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number TL1TR001880 (SES). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research reported in the publication was supported by the Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania (SES), The Children’s Hospital of Philadelphia Comprehensive Vascular Anomalies Frontier Program (HH), The Children’s Hospital of Philadelphia K-readiness grant (SES), Uplifting Athletes and the Lymphangiomatosis Gorham’s Disease Alliance (SES).
HH and The Children’s Hospital of Philadelphia are equity holders in Nobias Therapeutics Inc., developing MEK inhibitor therapy for complex lymphatic anomalies. Other authors declare no competing interests.
Ethics approval and consent to participate
The Children’s Hospital of Philadelphia Institutional Review Board approved a registry and biorepository study (PI YD). Informed consent was obtained from all participants as required by the IRB.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Liu, M., Smith, C.L., Biko, D.M. et al. Genetics etiologies and genotype phenotype correlations in a cohort of individuals with central conducting lymphatic anomaly. Eur J Hum Genet (2022). https://doi.org/10.1038/s41431-022-01123-9